CA2541117A1 - Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule - Google Patents

Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule Download PDF

Info

Publication number
CA2541117A1
CA2541117A1 CA002541117A CA2541117A CA2541117A1 CA 2541117 A1 CA2541117 A1 CA 2541117A1 CA 002541117 A CA002541117 A CA 002541117A CA 2541117 A CA2541117 A CA 2541117A CA 2541117 A1 CA2541117 A1 CA 2541117A1
Authority
CA
Canada
Prior art keywords
bioactive agent
lipid
particles
agent delivery
delivery particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002541117A
Other languages
English (en)
Inventor
Robert O. Ryan
Michael N. Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Oakland Research Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/004295 external-priority patent/WO2004073684A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2541117A1 publication Critical patent/CA2541117A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002541117A 2003-10-01 2004-08-06 Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule Abandoned CA2541117A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50803503P 2003-10-01 2003-10-01
US60/508,035 2003-10-01
USPCT/US04/004295 2004-02-13
PCT/US2004/004295 WO2004073684A2 (fr) 2003-02-14 2004-02-13 Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
PCT/US2004/025412 WO2005039534A1 (fr) 2003-10-01 2004-08-06 Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule

Publications (1)

Publication Number Publication Date
CA2541117A1 true CA2541117A1 (fr) 2005-05-06

Family

ID=34910664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002541117A Abandoned CA2541117A1 (fr) 2003-10-01 2004-08-06 Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule

Country Status (5)

Country Link
EP (1) EP1677763A1 (fr)
JP (2) JP4786538B2 (fr)
AU (1) AU2004283078A1 (fr)
CA (1) CA2541117A1 (fr)
WO (1) WO2005039534A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376875T3 (es) 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
GB0513096D0 (en) 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
CA2619917C (fr) * 2005-08-29 2013-04-23 Technische Universitaet Muenchen Proteines de soie arachneenne modifiees
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
CA2730737A1 (fr) * 2008-07-15 2010-01-21 Novartis Ag Compositions de peptides amphipatiques immunogenes
CA2780482A1 (fr) 2008-11-17 2010-05-10 Anil K. Sood Particules de hdl pour administration d'acides nucleiques
WO2013033513A1 (fr) * 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Nanoparticules ciblant l'apoptose
ES2608857T3 (es) 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
SI3043814T1 (sl) 2013-09-13 2021-04-30 Salipro Biotech AB, Greenhouse Labs Antigen in postopek za proizvodnjo le-tega
WO2015138992A1 (fr) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Administration de 3-bromopyruvate dans les mitochondries
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
US11229602B2 (en) * 2016-01-07 2022-01-25 Western University Of Health Sciences Formulations for treating bladder cancer
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609399A1 (fr) * 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
US7220833B2 (en) * 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
ES2376875T3 (es) * 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo

Also Published As

Publication number Publication date
WO2005039534A8 (fr) 2005-09-09
JP2007526907A (ja) 2007-09-20
JP4786538B2 (ja) 2011-10-05
EP1677763A1 (fr) 2006-07-12
JP2010248255A (ja) 2010-11-04
WO2005039534A1 (fr) 2005-05-06
AU2004283078A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CA2515892C (fr) Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
JP2006517972A5 (fr)
JP2010248255A (ja) 親油性薬物送達ビヒクルおよびその使用方法
JP2010248255A6 (ja) 親油性薬物送達ビヒクルおよびその使用方法
US6592894B1 (en) Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
JP4076026B2 (ja) リポソームディフェンシン
Agrawal et al. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters
WO2009062299A1 (fr) Compositions de liposomes stabilisés par un gel, leurs procédés de préparation et leurs utilisations
EP1259224A2 (fr) Nouvelles formulations cochleaires, procede de preparation et utilisation de celles-ci dans l'administration de molecules biologiquement utiles
HK1156863A (en) Lipophilic drug delivery vehicle and methods of us thereof
Pylypenko “QUALITY BY DESIGN” IN LIPOSOMAL DRUGS CREATION
AU2004200967A1 (en) Novel hydrogel isolated ochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules

Legal Events

Date Code Title Description
FZDE Dead